CN114934076A - Preparation method and application of zebra fish hoxba gene cluster deletion mutant - Google Patents
Preparation method and application of zebra fish hoxba gene cluster deletion mutant Download PDFInfo
- Publication number
- CN114934076A CN114934076A CN202210760774.9A CN202210760774A CN114934076A CN 114934076 A CN114934076 A CN 114934076A CN 202210760774 A CN202210760774 A CN 202210760774A CN 114934076 A CN114934076 A CN 114934076A
- Authority
- CN
- China
- Prior art keywords
- hoxba
- gene cluster
- grna
- zebra fish
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091008053 gene clusters Proteins 0.000 title claims abstract description 83
- 241000252212 Danio rerio Species 0.000 title claims abstract description 79
- 238000012217 deletion Methods 0.000 title claims abstract description 48
- 230000037430 deletion Effects 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 108020005004 Guide RNA Proteins 0.000 claims abstract description 53
- 108091033409 CRISPR Proteins 0.000 claims abstract description 24
- 101150086006 hoxb1a gene Proteins 0.000 claims abstract description 24
- 101150029593 hoxb13a gene Proteins 0.000 claims abstract description 21
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 15
- 201000010099 disease Diseases 0.000 claims abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 7
- 239000013612 plasmid Substances 0.000 claims abstract description 7
- 238000013518 transcription Methods 0.000 claims abstract description 7
- 230000035897 transcription Effects 0.000 claims abstract description 7
- 238000000338 in vitro Methods 0.000 claims abstract description 6
- 238000012258 culturing Methods 0.000 claims abstract description 5
- 238000002156 mixing Methods 0.000 claims abstract description 5
- 238000012408 PCR amplification Methods 0.000 claims abstract description 4
- 230000008827 biological function Effects 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims abstract description 4
- 238000001514 detection method Methods 0.000 claims description 18
- 241000251468 Actinopterygii Species 0.000 claims description 11
- 230000035772 mutation Effects 0.000 claims description 11
- 230000002159 abnormal effect Effects 0.000 claims description 8
- 230000000747 cardiac effect Effects 0.000 claims description 8
- 210000002257 embryonic structure Anatomy 0.000 claims description 7
- 238000011144 upstream manufacturing Methods 0.000 claims description 7
- 238000007363 ring formation reaction Methods 0.000 claims description 6
- 238000012216 screening Methods 0.000 claims description 6
- 230000009067 heart development Effects 0.000 claims description 5
- 206010030113 Oedema Diseases 0.000 claims description 4
- 238000010171 animal model Methods 0.000 claims description 4
- 230000036244 malformation Effects 0.000 claims description 4
- 210000001161 mammalian embryo Anatomy 0.000 claims description 4
- 238000000520 microinjection Methods 0.000 claims description 4
- 238000009401 outcrossing Methods 0.000 claims description 4
- 101100396069 Danio rerio hoxb13a gene Proteins 0.000 claims description 3
- 230000001131 transforming effect Effects 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 238000013461 design Methods 0.000 abstract description 5
- 238000000746 purification Methods 0.000 abstract description 2
- 108020004414 DNA Proteins 0.000 description 19
- 238000010362 genome editing Methods 0.000 description 11
- 239000012634 fragment Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 238000012163 sequencing technique Methods 0.000 description 8
- 108700005087 Homeobox Genes Proteins 0.000 description 6
- 238000003209 gene knockout Methods 0.000 description 6
- 238000010453 CRISPR/Cas method Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000010354 CRISPR gene editing Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 2
- 101100071833 Danio rerio hoxb1a gene Proteins 0.000 description 2
- 108091028113 Trans-activating crRNA Proteins 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000005782 double-strand break Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091092236 Chimeric RNA Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 101100396068 Danio rerio hoxb10a gene Proteins 0.000 description 1
- 101100451926 Danio rerio hoxb7a gene Proteins 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- LLQPHQFNMLZJMP-UHFFFAOYSA-N Fentrazamide Chemical compound N1=NN(C=2C(=CC=CC=2)Cl)C(=O)N1C(=O)N(CC)C1CCCCC1 LLQPHQFNMLZJMP-UHFFFAOYSA-N 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241001098657 Pterois Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 238000010459 TALEN Methods 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 101150038500 cas9 gene Proteins 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 230000008143 early embryonic development Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 101150014569 hoxb2a gene Proteins 0.000 description 1
- 101150113570 hoxb3a gene Proteins 0.000 description 1
- 101150040257 hoxb4a gene Proteins 0.000 description 1
- 101150113150 hoxb5a gene Proteins 0.000 description 1
- 101150052542 hoxb6a gene Proteins 0.000 description 1
- 101150083905 hoxb8a gene Proteins 0.000 description 1
- 101150012562 hoxb9a gene Proteins 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000017448 oviposition Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108010008359 protein kinase C lambda Proteins 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knockout animals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/40—Fish
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0375—Animal model for cardiovascular diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/80—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in fisheries management
- Y02A40/81—Aquaculture, e.g. of fish
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Environmental Sciences (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Farming Of Fish And Shellfish (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses a preparation method and application of a zebra fish hoxba gene cluster deletion mutant, which comprises the following steps: determining that knockout targets of the hoxba gene cluster are respectively located on the 1 st exon of the hoxb13a gene and the 1 st exon of the hoxb1a gene to design gRNA sequences, performing PCR amplification by using a gRNA backbone plasmid as a template, performing PCR product purification and in vitro transcription to obtain gRNAs, mixing the gRNAs of the hoxb13a and the hoxb1a with a Cas9 protein, introducing the mixture into zebra fish, and culturing to obtain the stably inherited hoxba gene cluster deletion mutant. The invention provides a method for knocking out a plurality of continuous genes on a genome together and obtaining a stable mutant, and meanwhile, the phenotype of the mutant lays a foundation for researching the biological function of the hoxba gene cluster and diseases related to the deletion of the hoxba gene cluster.
Description
Technical Field
The invention belongs to the field of molecular biology, and particularly relates to a preparation method and application of a zebra fish hoxba gene cluster deletion mutant.
Background
The CRISPR-Cas9 is a third-generation gene editing technology after the gene editing technologies such as ZFN, TALENs and the like are introduced, and in a few years, the CRISPR-Cas9 technology is popular in the world, becomes one of the existing technologies with high efficiency, simplicity, low cost and easy operation in gene editing and gene modification, and becomes a mainstream gene editing system at present. The CRISPR/Cas9 system is based on a prokaryotic immune mechanism, can prevent nucleic acid invasion, and belongs to an adaptive immune defense mechanism of bacteria and archaea. It is produced during the course of the continuous evolution of organisms and is used to protect their own genome from interference by foreign nucleic acids. As early as 1987, discovered by researchers at the University of Osaka (Osaka University), in 2012, Doudna and Charpentier combined with each other to modify the CRISPR/Cas system of Streptococcus pyogenes of WT to integrate tracrRNA and crRNA into a single strand, which is called crRNA: tracrRNA chimera, i.e., the present gRNA. The activity of the Cas9 can be started by complementary pairing of the chimeric RNA and the corresponding sequence of the target DNA, and the DNA is cut, so that the research lays a foundation that the CRISPR/Cas becomes a gene editing tool, and the CRISPR/Cas also becomes a gene editing technology with more applications in model animal zebra fish due to the convenience of operation. In 2013, scientists worked to implement the CRISPR/Cas system for genome editing in human cells. Cas 9-mediated gene editing step: firstly, the Cas9 endonuclease cuts genomic DNA under the mediation of gRNA, and Double Strand Break (DSB) occurs in DNA; the fragmented DNA will then be repaired by the cell's own DNA repair system.
Zebrafish have made progress in developmental biology, oncology, toxicology, reproductive research, genetics, neurobiology, environmental science, stem cell research, regenerative medicine, and other fields because of their small size and rapid growth. Zebrafish, as the best model animal in developmental genetics, are powerful tools to assist in the study of the human genome. Zebra fish is also a good model for drug discovery and development, has been widely applied to human disease model research, new drug screening, drug toxicity and safety evaluation, and currently has more than 8000 mutants of zebra fish, wherein about 1/4 becomes a human disease model, and is an ideal gene editing tool at present. At present, multiple genes or small fragment gene knockout is carried out by using multiple gRNAs and Cas9 together in organisms such as yeast, rice, mice and the like, but few reports are carried out on the deletion of fragments of more than 100kb in zebra fish by using a CRISPR/Cas9 technology.
The Hox gene is a large family of transcription factors containing homeoboxes, the full name of homeotic genes. They are arranged in clusters on chromosomes and are distributed on different chromosomes. The Hox gene family controls the construction of body morphology during early embryonic development, and mutation of the Hox gene often causes corresponding deformity of corresponding parts of the body. Related reports show that the Hox gene plays an important role in the development and formation of vertebrate hearts. Medina-Martinez et al firstly constructed a mouse mutant strain with a HoxB gene cluster large fragment deletion of 90kb in total (except Hoxb 13) of Hoxb1-Hoxb9 by using a homologous recombination gene knockout method in 2000, but the whole HoxB gene cluster is not completely knocked out by the mouse strain, and a specific mechanism of an abnormal heart phenotype of the mouse strain is to be deeply analyzed. It has also been found that clinical patients lack part of the HoxB gene cluster (HoxB1-HoxB9) or multiple HoxB genes, and thus have a series of clinical manifestations of growth retardation, cardiopulmonary-cerebral dysplasia, abnormal hands and feet, congenital facial deformity, etc., with the most serious of the patients dying in the four months after birth. However, these studies do not deeply explore the downstream regulatory pathways of the gene, and further elucidation and research are needed.
Disclosure of Invention
The invention mainly aims to provide a preparation method of zebra fish hoxba gene cluster deletion mutants, which utilizes zebra fish as a model organism, designs a target sequence through a CRISPR/Cas9 technology, carries out gene editing on the hoxba gene cluster to realize the targeted knockout of a target gene, and provides a construction thought for commonly knocking out a plurality of continuous genes on a genome to obtain stable mutants.
The invention also aims to provide application of the zebra fish hoxba gene cluster deletion mutant as an animal model in researching the biological function of the hoxba gene cluster and diseases related to hoxba gene cluster deletion, wherein the hoxba cluster plays an important role in heart development, obvious defects can be shown on the heart when the gene is deleted, and the animal model constructed by the zebra fish hoxba gene cluster deletion mutant can provide a mode and a method for researching related diseases such as abnormal heart development and the like.
In order to achieve the purpose, the invention adopts the following technical scheme:
the invention provides a preparation method of a zebra fish hoxba gene cluster deletion mutant, which comprises the following steps:
s1, determining a hoxba gene cluster knockout target to design gRNA sequences on the 1 st exon of zebrafish hoxb13a gene and the 1 st exon of hoxb1a gene;
s2, designing an upstream primer T7-hoxb13a-sfd, T7-hoxb1a-sfd and a downstream gRNA reverse primer for synthesizing gRNA;
s3, respectively carrying out PCR amplification by using primers T7-hoxb13a-sfd, T7-hoxb1a-sfd and a downstream gRNA reverse primer by using a gRNA framework plasmid as a template;
s4, carrying out in vitro transcription on the PCR product obtained in the step S3, and transforming to obtain hoxb13a gRNA and hoxb1a gRNA;
s5, mixing the hoxb13a gRNA and the hoxb1a gRNA with the Cas9 protein, and then performing microinjection and introduction into a zebra fish one-cell-stage embryo;
s6, culturing to obtain the stably inherited zebra fish hoxba gene cluster deletion mutant.
Preferably, in step S1, the target gRNA sequence is
hoxb13a:GGATGAGCTGAAGAATATGG(SEQ ID NO:1)
hoxb1a:GGAACTGGGACAACAAGTTA(SEQ ID NO:2)
The sequence of primer T7-hoxb1a-sfd is
The sequence of a downstream primer R1(trans reverse), i.e., a gRNA reverse primer, is
AAAAAAAGCACCGACTCGGTGCCAC(SEQ ID NO:5)。
Preferably, in step S4, the sequence of hoxb13a gRNA is
TAATACGACTCACTATAGGATGAGCTGAAGAATATGGGTTTTAGAGCTAGAAATAGCGGACAGATTCATGTCCTGGACGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCTTTTTTT(SEQ ID NO:6)。
The sequence of the hoxb1a gRNA is
TAATACGACTCACTATAGGAACTGGGACAACAAGTTAGTTTTAGAGCTAGAAATAGCGGACAGATTCATGTCCTGGACGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCTTTTTTT(SEQ ID NO:7)。
Preferably, in step S5, the final concentrations of both hoxb13a gRNA and hoxb1a gRNA are 100ng/μ L, the final concentration of Cas9 protein is 800ng/μ L, and the total volume is 1 nL.
Preferably, step S6 specifically includes the following steps:
a1, respectively taking zebra fish with gRNA and Cas9 protein introduced and wild-type zebra fish embryos which are not injected for hoxba gene cluster knockout detection, and determining hoxba gene cluster knockout positive F 0 Culturing to adult fish;
a2, knocking out hoxba gene cluster to be positive F 0 Carrying out heritability and effective mutation detection on the adult fish and wild zebra fish outcrossing, and screening heritability effective mutation F 1 Feeding to adult fish, and obtaining hoxba gene cluster F through genotype identification 1 Mutant zebrafish;
a3, cluster F of the same mutated hoxba gene 1 Carrying out internal crossing on mutant zebra fish to obtain a hoxba gene cluster F 2 Mutant zebrafish;
a4, identified as F 2 Homozygotes of the deletion of the hoxba gene cluster in the generations, namely stably inherited zebrafish hoxba gene cluster deletion mutants.
Preferably, in step a1, the detection primers used for the hoxba gene cluster knockout detection include:
the upstream primer hoxb13 a-F: CGTCACGTGGTACTGCTCTC (SEQ ID NO: 8);
the downstream primer hoxb1 a-R: CAATCCACCTGTTTTGGGGG (SEQ ID NO: 9);
the upstream primer hoxb1 a-F: ACGCTGATGGACGACTTTACG (SEQ ID NO:10)
More preferably, step S6 includes the steps of:
(1) designing primers around the target point, so that the distance between the primers and the two sides of the target point is greater than 100bp, and the absolute value of the difference of the distances between the primers and the target point is greater than 100 bp; selecting a pair of healthy WT zebra fishes as parents, cutting tails to perform PCR, directly sequencing PCR products, detecting whether genes to be knocked out of parent fishes are homozygotes, requiring that target sequences of adult fishes to be injected are homozygotes, and if sequencing results show that the target sequences are heterozygotes, reselecting the adult fishes to be injected;
(2) microinjecting gRNA and Cas9 protein into zebra fish, and mixing the gRNA with the final concentration of 100 ng/mu L of an injection system; cas9 protein: 800 ng/mu L, and the total volume is 1 nL;
(3) picking out dead eggs in the evening on the injection day, changing half of fresh water, changing water once in the morning and at the evening, 48h after fertilization, detecting double-outer-side primer PCR, and knocking out successfully F 0 Feeding zebra fish;
(4) after 3-4 months of sexual maturity of zebra fish, mutating F 0 Hybridizing zebra fish with wild zebra fish to obtain heterozygote with certain probability, collecting embryo, extracting genome, performing PCR with detection primer, cloning with TA, sequencing to determine genotype, and determining heritable F with effective mutation 1 Feeding zebra fish;
(5) after 3-4 months of sexual maturity, mutated F 1 And (3) cutting tails of adult male and female zebra fish, carrying out genotype identification and screening, and mating the mutant zebra fish again to obtain the homozygous hoxba gene cluster deletion mutant zebra fish.
Preferably, the zebra fish hoxba -/- The mutant is observed with pericardial cavity edema and abnormal cardiac development and malformation of cardiac cyclization at 3.5 dpf.
The invention also provides application of the zebra fish hoxba gene cluster deletion mutant as an animal model in researching biological functions of the hoxba gene cluster and diseases related to hoxba gene cluster deletion, wherein the zebra fish hoxba gene cluster deletion mutant is prepared by any one of the preparation methods of the zebra fish hoxba gene cluster deletion mutant.
Compared with the prior art, the invention has the following beneficial effects:
1) the invention designs gRNA targets on the 1 st exon of a hoxb13a gene and the 1 st exon of a hoxb1a gene respectively by using a CRISPR/Cas9 technology for the first time to delete large fragments of the hoxb gene cluster, wherein the hoxb gene cluster comprises 13 genes in total and has the full length of 116.9kb, and the hoxb1a, the hoxb2a, the hoxb3a, the hoxb4a, the hoxb5a, the hoxb6a, the hoxb7a, the hoxb8a, the hoxb9a, the hoxb10a, the hoxb11a, the hoxb12a and the hoxb13a are sequentially arranged from 3 'to 5', so that the specific knockout of the hoxb gene cluster is successfully realized, the zebra fish hoxb gene cluster deletion mutant is obtained, a method is provided for jointly knocking out a plurality of continuous genes on a genome and obtaining a stable mutant, and the phenotype of the hoxb gene cluster related to biological deletion of the hoxb gene cluster.
2) The hoxba gene cluster mutation can be stably inherited, and is convenient for the subsequent deep research on the functional mechanism of the hoxba gene cluster.
3)hoxba -/- The mutant zebra fish has obvious phenotype, and obvious cardiac development malformation phenomena such as pericardial cavity edema, abnormal cardiac cyclization and the like are observed at 3.5 dpf.
4) The invention realizes the site-specific knockout of the target gene by the knockout of large fragments of the genome without interfering the functions of other gene clusters, thereby providing a basis for subsequent related researches.
Drawings
FIG. 1 is a CRISPR/Cas 9-mediated deletion pattern of zebra fish hoxba gene cluster.
FIG. 2 shows the targeting sequence information and sites for the hoxba gene cluster deletion at the first exon of hoxb13a and the first exon of hoxb1a, respectively.
FIG. 3 shows the PCR detection of F with double outer primers in the process of mutant screening 0 ,F 1 ,F 2 Zebrafish genotype.
FIG. 4 is a graph of sequencing peaks showing successful deletion of the hoxba gene cluster in homozygous mutants.
FIG. 5 shows hoxba Gene cluster F 1 And (5) detecting the genotype of the mutant by PCR.
FIG. 6 is the gene sequence of homozygous mutant of the hoxba gene cluster.
FIG. 7 is a phenotypic map of mutations in zebrafish embryos following deletion of the hoxba gene cluster. Wild type (a) and hoxba mutant (b) cardiac phenotype at 3.5 dpf; (c) the heart cyclization angle of the hoxba mutant was significantly increased compared to the wild type. n is more than or equal to 3, and P is 0.00537. *: p <0.05, x: p <0.01, x: p < 0.001. Scale is 0.1 mm.
FIG. 8 is a phenotypic map of mutations in zebrafish embryos following deletion of the hoxba gene cluster. Heart phenotype of wild type (a) and hoxba mutant (d, g) at 3.5 dpf; the number indicates the location of the pericardial enlargement, (b, e, h) the heart region is enlarged and the black dashed line depicts the pericardial outline; (c, f, i) cardiac fluorescence labeling, cardiac cyclization of hoxba mutant was significantly abnormal compared to wild type, white dashed line delineating heart. The scale (a, d, g) is 0.2mm, and the scale (c, f, i) is 0.1 mm.
Detailed Description
The present invention will be described in detail with reference to examples. The following examples will assist those skilled in the art in further understanding the invention, but are not intended to limit the invention in any way. It should be noted that it would be apparent to those skilled in the art that several modifications and improvements can be made without departing from the inventive concept. All falling within the scope of the present invention.
Examples
1 Material and apparatus
1.1 Fish for experiments
The zebra fish used in the experiment is derived from a zebra fish platform of the aquatic product and life college of Shanghai ocean university.
1.2 plasmids
gRNA backbone plasmids were derived from literature: chang N, Sun C, Gao L, Zhu D, Xu X, Zhu X, Xiong JW, Xi JJ. genome editing with RNA-guided Cas9 nucleic in zebrafish embryo, Cell Res, 2013, 23(4): 465-.
1.3 Primary reagents
DNAClean&Contentrator-5(ZYMO RESEARCH,D4004),T7 in vitro Transcription Kit (Ambion, AM1314), ethanol (absolute ethanol) (national drug group chemical reagent Co., Ltd., 10009218), GenCrispr NLS-Cas9-NLS (Kinsry, Z03389-25), general DNA purification Kit (TIANGEN, DP204-03), Premix Taq TM (Ex Taq TM Version 2.0 plus dye)(TAKARA,RR902),DNA Marker I(TIANGEN,MD101-02),T7endonuclease 1(NEW ENGLANDM0302L), DH5a competent cells (Tiangen Biotechnology Co., Ltd., CB101-03), 2BeasyTaq PCR Supermix (+ dye) (TAKARA, AS111-12), LB Broth (Shanghai Biolabs, D915KA6602), Rapid plasmid Mini kit (TIANGEN, DP105), LB Broth agar (Shanghai Biolabs, D911KA6566), pMD TM 19-T Vector Cloning Kit(TAKARA,6013)。
1.4 Main Instrument
PCR instrument (brand: BIO-RAD, model: c1000 Touch) TM Thermal Cycler), small centrifuge (brand: eppendorf, model: centrifuge 5424), shaking mixer (brand: VORTEX-GENIE, model: G560E), ultraviolet spectrophotometer (brand: thermo Scientific, model: nanodrop 2000C), autoclave (brand: SANYO, type: MLS-3780), electrophoresis apparatus (brand: BIO-RAD, type: PowerPac Basic), photographic glue apparatus (brand: Bio-Rad, model: gel Doc EZ Imager), electronic balance (brand: METTLER TOLEDO, type: AL104), Milli-Q Direct 8 ultra pure water system (brand: millipore, type: Milli-Q Direct 8), vertical pin puller (brand: NARISHIGE, model number: PC-10), constant temperature shaking table (brand: innova, type: 40R), needle grinder (brand: NARISHIGE, type: EG-400), micro-syringe pump (brand: WARNER, model: PLI-100A), thermostat water bath (brand: fine macro, type: h1401438, DK-8D), glassCapillary (brand: WPI, model: TW100F-4), 4 ℃ refrigerator (brand: Haier, model: HYC-610), 40 ℃ low temperature refrigerator (brand: Haier, model: DW-40L508), 80 ℃ ultra-low temperature refrigerator (brand: Pana-sonic, model: MDF-U53V).
2 method of experiment
2.1 design and screening of hoxba Gene knockout targets
(1) Specificity detection and selection analysis of hoxba Gene Cluster targets
a. Downloading sequence: the gene sequences of zebrafish hoxb13a and hoxb1a were looked up and downloaded in the Ensembl database.
b. Designing a target spot: designing targets on exon sequences behind hoxb13a and hoxb1a gene ATG by using http:// zifit.partners.org/ZiFiT/ChoiceMenu.aspx website to obtain two target sequences of hoxb13a, namely a phi GGATGAGCTGAAGAATATGG; ② GGACGTATCGACTTCAAGTT. Obtaining a sequence of three target points of hoxb1a, namely a phi GGAACTGGGACAACAAGTTA; GGTGCGTACTGCGGGGCACA; ③ GGCCTCTCAAGGAACGGAGA. Through experimental verification, a hoxb13a target point is found: GGATGAGCTGAAGAATATGG (SEQ ID NO:1), and hoxb1a target: GGAACTGGGACAACAAGTTA (SEQ ID NO:2) showed the best knock-out effect, and the specific target information is shown in Table 1.
Table 1: hoxb13a and hoxb1a target site sequences
c. And (3) target specificity detection: and (3) carrying out blast comparison on the designed target point sequence at the NCBI website to verify the target point specificity.
d. Parent detection: the WT zebra fish used for gene knockout is trimmed and subjected to alkaline lysis to obtain genome DNA, and a segment of sequence near a target point is amplified by PCR.
e. Sequencing and identifying: and (3) sequencing the PCR product, comparing a peak diagram with a sequence, and confirming that the parent is a homozygote without natural mutation, thereby ensuring that the subsequently prepared mutant is caused by gene knockout.
(2) Designing a target detection primer: the designed primers should be ensured to be more than 100bp away from both sides of the target, the difference between the distance from the upstream primer to the target and the distance from the downstream primer to the target should be more than 100bp and at least 50bp, the primer amplification should have specificity, the amplified fragment is about 500bp, and the primers are synthesized by Shanghai biological engineering Limited company (Table 2).
Table 2: primer information for experiments
(3) gRNA product synthesis: using the gRNA backbone plasmid as a template, primers T7-hoxb13a-sfd, T7-hoxb1a-sfd were used to amplify fragments with the gRNA reverse primer and 2 × EasyTaq PCR SuperMix (+ dye) respectively and purified with a kit.
(4) In vitro transcription: reaction system:
TABLE 3
Nuclease-free Water | to 20μL |
DNA template | 1μg |
10×Transcription Buffer | 2μL |
10mM ATP | 1μL |
10mM CTP | 1μL |
10mM GTP | 1μL |
10mM UTP | 1μL |
T7Enzyme Mix | 2μL |
Note that: finally, 10 × Transmission Buffer and T7Enzyme mix were added
Mixing, centrifuging for a short time, and incubating at 37 deg.C for 80 min; then, 1. mu.L of TURBO DNase was added to the system and mixed well, centrifuged briefly and incubated at 37 ℃ for 15 min.
(5) Purifying gRNA:
a. to 20. mu.L of the in vitro transcription system, 2.5. mu.L of 4M LiCl and 100. mu.L of body absolute ethanol were added, mixed well and centrifuged briefly and then placed in a freezer at-80 ℃ for at least 1 h.
b. After the time, the cells were removed from the freezer, centrifuged at 12000rmp at 4 ℃ for 15 min. The supernatant was discarded and the precipitate was washed with 70% ethanol. Centrifuge at 8000rmp for 5min at 4 ℃. After discarding the supernatant, the centrifuge tube was placed in a fume hood to volatilize the ethanol.
c. Adding appropriate amount of DEPC water to dissolve gRNA precipitate according to the size of the precipitate.
d. The concentration and OD values were measured by Nanodrop and electrophoresis.
Wherein the sequence of hoxb13a gRNA is
TAATACGACTCACTATAGGATGAGCTGAAGAATATGGGTTTTAGAGCTAGAAATAGCGGACAGATTCATGTCCTGGACGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCTTTTTTT(SEQ ID NO:6);
The hoxb1a gRNA has the sequence
TAATACGACTCACTATAGGAACTGGGACAACAAGTTAGTTTTAGAGCTAGAAATAGCGGACAGATTCATGTCCTGGACGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCTTTTTTT(SEQ ID NO:7)。
2.2 microinjection
The gRNA was mixed with Cas9 protein (purchased from gencriprpr NLS-Cas9-NLS (chryssper, Z03389-25)), and the mixed material was injected into zebrafish one-cell stage embryos using a microinjection instrument, leaving a batch of uninjected embryos as a control for each injection. Mixed injection final concentration: gRNA 100 ng/. mu.L, Cas9 protein 800 ng/. mu.L.
2.3 detection of successful knockout and knockout efficiency (PCR detection)
a. Extraction of fish egg genome
Each group of 5 eggs was incubated with 35. mu.L of 50mM NaOH at 95 ℃ for 20min, shaken, and centrifuged once. Then, 3.5. mu.L of 1M Tris-HCl (pH. apprxeq.8.0) was added thereto, followed by vigorous shaking and centrifugation.
b. PCR amplification of fragments of interest
And amplifying the target fragment according to the primer designed near the target point.
And (3) PCR reaction system:
TABLE 4
H 2 O | to 25μL |
Enzyme | 12.5μL |
F | 0.5μL |
R | 0.5μL |
Form panel | 10ng |
And (3) PCR reaction conditions:
pre-denaturation at 98 ℃ for 2 sec; denaturation at 98 ℃ for 10sec, annealing at 60.3 ℃ for 30sec, and extension at 72 ℃ for 1min for 32 cycles; further extension at 72 deg.C for 5 min; storing at 4 ℃.
2% agarose gel 120V electrophoresis for 25 min.
c. Electrophoretic detection
And (3) imaging the electrophoresed agarose gel by using a gel electrophoresis imager after electrophoresis, observing a target band, and judging whether the knockout is successful.
2.4 identification of genotype of mutant zebra fish with deletion homozygous for hoxba Gene Cluster
And carrying out genotype screening and identification on different deletion types.
3 results of the experiment
3.1 construction of mutant hoxba Gene Cluster
3.1.1 hoxbaF 0 Results of Gene knockout assay
The PCR result shows that the hoxba gene cluster is knocked out successfully. Sequencing peak plots showed that the genomic sequence between the hoxb13a gene target and the hoxb1a gene target was deleted, demonstrating successful knock-out (fig. 1, 2, 3, 4).
3.1.2 hoxbaF 0 germline transmission test result
Taking 20 tail hoxba F 0 Carrying out outcrossing on adult fish successfully knocked out by gene detection and wild zebra fish to obtain F 1 5 embryos are placed in one tube, 3-4 tubes are taken for double-lateral primer PCR identification, and the result shows that 1 zebra fish transmits mutation to offspring (figures 1, 2, 3 and 4).
3.1.3hoxba F 1 Heterozygous mutant zebra fish genotype identification
And (3) carrying out tail shearing detection on the hoxba genes of the zebra fish obtained by 71-tail outcrossing, carrying out PCR detection to obtain 48 positive zebra fish, and carrying out sequencing verification to confirm that large fragment deletion of hoxba gene clusters occurs (fig. 5 and 6).
3.1.4hoxba F 2 Mutant zebra fish phenotype observation photographing
(1) The hoxba gene cluster hybrid mutant was subjected to in vivo crossing, collected after egg laying and cultured for early embryo development observation, and significant cardiac malformations such as pericardial edema and abnormal cardiac cyclization were observed at 3.5dpf (fig. 7).
(2) To further characterize the hoxba gene cluster mutant, 3.5dpf hoxba gene cluster-deleted mutants and wild-type hearts were photographed for visualization and use in subsequent genotyping (FIG. 8).
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents, improvements and the like that fall within the spirit and principle of the present invention are intended to be included therein.
Sequence listing
<110> Shanghai ocean university
Preparation method and application of <120> zebra fish hoxba gene cluster deletion mutant
<141> 2022-06-30
<160> 10
<170> SIPOSequenceListing 1.0
<210> 1
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 1
<210> 2
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 2
<210> 3
<211> 57
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 3
taatacgact cactatagga tgagctgaag aatatgggtt ttagagctag aaatagc 57
<210> 4
<211> 57
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 4
taatacgact cactatagga actgggacaa caagttagtt ttagagctag aaatagc 57
<210> 5
<211> 25
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 5
aaaaaaagca ccgactcggt gccac 25
<210> 6
<211> 120
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 6
taatacgact cactatagga tgagctgaag aatatgggtt ttagagctag aaatagcgga 60
cagattcatg tcctggacgt tatcaacttg aaaaagtggc accgagtcgg tgcttttttt 120
<210> 7
<211> 120
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 7
taatacgact cactatagga actgggacaa caagttagtt ttagagctag aaatagcgga 60
cagattcatg tcctggacgt tatcaacttg aaaaagtggc accgagtcgg tgcttttttt 120
<210> 8
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 8
cgtcacgtgg tactgctctc 20
<210> 9
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 9
<210> 10
<211> 21
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 10
acgctgatgg acgactttac g 21
Claims (9)
1. The preparation method of the zebra fish hoxba gene cluster deletion mutant is characterized by comprising the following steps of:
s1, determining a target point of hoxba gene cluster knockout, and designing gRNA sequences on the 1 st exon of the zebra fish hoxb13a gene and the 1 st exon of the hoxb1a gene respectively;
s2, designing an upstream primer T7-hoxb13a-sfd, a T7-hoxb1a-sfd and a downstream gRNA reverse primer of the synthetic gRNA;
s3, respectively carrying out PCR amplification by using upstream primers T7-hoxb13a-sfd, T7-hoxb1a-sfd and a gRNA reverse primer by using a gRNA framework plasmid as a template;
s4, carrying out in vitro transcription on the PCR product obtained in the step S3, and transforming to obtain hoxb13a gRNA and hoxb1a gRNA;
s5, mixing the hoxb13a gRNA and the hoxb1a gRNA with the Cas9 protein, and then performing microinjection and introduction into a zebra fish one-cell-stage embryo;
s6, culturing to obtain the stably inherited zebra fish hoxba gene cluster deletion mutant.
2. The method for preparing the zebra fish hoxba gene cluster deletion mutant according to claim 1, wherein in step S1, the gRNA sequence of the hoxb13a gene is shown as SEQ ID NO:1, and the gRNA sequence of the hoxb1a gene is shown as SEQ ID NO: 2.
3. The method for preparing the zebra fish hoxba gene cluster deletion mutant according to claim 1, wherein in step S2, sequences of T7-hoxb13a-sfd, T7-hoxb1a-sfd and gRNA reverse primers are shown as SEQ ID NO. 3, SEQ ID NO. 4 and SEQ ID NO. 5, respectively.
4. The method for preparing the zebra fish hoxba gene cluster deletion mutant according to claim 1, wherein in step S4, the sequence of hoxb13a gRNA is shown as SEQ ID NO. 6, and the sequence of hoxb1a gRNA is shown as SEQ ID NO. 7.
5. The method for preparing the zebra fish hoxba gene cluster deletion mutant according to claim 1, wherein in step S5, the final concentration of each of hoxb13a gRNA and hoxb1a gRNA is 100ng/μ L, the final concentration of Cas9 protein is 800ng/μ L, and the total volume is 1 nL.
6. The method for preparing the zebra fish hoxba gene cluster deletion mutant according to claim 1, wherein the step S6 specifically comprises the following steps:
a1, respectively taking zebra fish introduced with gRNA and Cas9 protein mixture and wild type uninjected zebra fish embryos for detecting hoxba gene cluster knockout efficiency, and determining F positive to hoxba gene cluster knockout 0 Culturing to adult fish;
a2, knocking out hoxba gene cluster to be positive F 0 Outcrossing adult fish and wild zebra fish, detecting heritability and effective mutation, screening heritability effective mutation F1, feeding to adult fish, and identifying genotype to obtain hoxba gene cluster F 1 Mutant zebrafish;
a3, cluster F of same mutated hoxba gene 1 Carrying out internal crossing on mutant zebra fish to obtain a hoxba gene cluster F 2 Mutant zebrafish;
a4, identified as F 2 Homozygotes of the hoxba gene cluster knockout in generations are deletion mutants of the stably inherited zebra fish hoxba gene cluster.
7. The method for preparing the zebra fish hoxba gene cluster deletion mutant as claimed in claim 6, wherein in step A1, the double outside primer PCR method is used to perform hoxba gene cluster knockout detection, and two pairs of detection primers hoxb13a-F/hoxb1a-R and hoxb1a-F/hoxb1a-R are used, wherein the sequences of the primers hoxb13a-F, hoxb1a-R and hoxb1a-F are shown as SEQ ID NO. 8, SEQ ID NO. 9 and SEQ ID NO. 10 respectively.
8. The method for preparing the zebrafish hoxba gene cluster deletion mutant according to claim 6, wherein the zebrafish hoxba gene cluster deletion mutant is characterized in that the zebrafish hoxba gene cluster deletion mutant is a mutant of zebrafish hoxba -/- The mutant is observed with pericardial cavity edema and abnormal cardiac development and malformation of cardiac cyclization at 3.5 dpf.
9. Use of a zebrafish hoxba gene cluster deletion mutant as an animal model for studying the biological function of the hoxba gene cluster and diseases associated with hoxba gene cluster deletion, said zebrafish hoxba gene cluster deletion mutant being obtainable by the method of preparation of a zebrafish hoxba gene cluster deletion mutant according to any one of claims 1 to 8.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210760774.9A CN114934076A (en) | 2022-06-30 | 2022-06-30 | Preparation method and application of zebra fish hoxba gene cluster deletion mutant |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210760774.9A CN114934076A (en) | 2022-06-30 | 2022-06-30 | Preparation method and application of zebra fish hoxba gene cluster deletion mutant |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114934076A true CN114934076A (en) | 2022-08-23 |
Family
ID=82868347
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210760774.9A Pending CN114934076A (en) | 2022-06-30 | 2022-06-30 | Preparation method and application of zebra fish hoxba gene cluster deletion mutant |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114934076A (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109628454A (en) * | 2019-01-30 | 2019-04-16 | 上海海洋大学 | The construction method of zebra fish glycogen storage disease gys1 and gys2 gene mutation body |
-
2022
- 2022-06-30 CN CN202210760774.9A patent/CN114934076A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109628454A (en) * | 2019-01-30 | 2019-04-16 | 上海海洋大学 | The construction method of zebra fish glycogen storage disease gys1 and gys2 gene mutation body |
Non-Patent Citations (5)
Title |
---|
KAZUYA YAMADA等: "An atlas of seven zebrafish hox cluster mutants provides insights into sub/neofunctionalization of vertebrate Hox clusters", 《DEVELOPMENT》, vol. 148, no. 11 * |
刘保池主编: "《细胞治疗临床研究》", 复旦大学出版社, pages: 62 * |
张绪帅: "CRISPR/Cas9系统介导的七鳃鳗和斑马鱼基因组编辑方法的建立与优化", 《中国优秀硕士学位论文全文数据库 基础科学辑》, pages 13 - 19 * |
李佳: "CRISPR/Cas9技术在斑马鱼基因修饰中的应用", 《生命科学》, vol. 27, no. 1, 31 January 2015 (2015-01-31), pages 29 * |
顾叶丹: "斑马鱼hoxb4a 在心脏发育中的功能研究", 《上海海洋大学学报》, 26 July 2021 (2021-07-26), pages 62 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108660161B (en) | Method for preparing chimeric gene-free knockout animal based on CRISPR/Cas9 technology | |
CN108707628B (en) | Preparation method of zebra fish notch2 gene mutant | |
CN106047930B (en) | Preparation method of Flox rat with conditional knockout of PS1 gene | |
CN110551759B (en) | Composition and method for improving recombination efficiency of transgenic cells | |
CN108707629A (en) | The preparation method of zebra fish notch1b gene mutation bodies | |
CN109628454B (en) | Construction method of zebra fish glycogen storage disease gys1 and gys2 gene mutant | |
CN106282231B (en) | Construction method and application of mucopolysaccharide storage disease type II animal model | |
CN108753834B (en) | Preparation method of zebra fish mutant with ddx27 gene deletion | |
CN110643636B (en) | Megalobrama amblycephala MSTNa & b gene knockout method and application | |
CN112980880B (en) | Method for constructing Fzd6-Q152E fixed-point mutation mouse model based on CRISPR/Cas9 and application | |
CN110541002A (en) | method for constructing zebra fish asap1b gene knockout mutant by using CRISPR/Cas9 technology | |
CN111154758A (en) | Method for knocking out zebra fish slc26a4 gene | |
CN105274141A (en) | Transgenic vector for target mutation of primordial germ cells, method for preparing transgenic vector and application thereof | |
CN116515825A (en) | SgRNA combination for knocking out zebra fish ddx18 gene and application thereof | |
CN114480497B (en) | Construction and application method of ep400 gene knockout zebra fish heart failure model | |
CN115807037A (en) | Genetic controllable tetraploid fish breeding method and triploid fish preparation method | |
CN114934076A (en) | Preparation method and application of zebra fish hoxba gene cluster deletion mutant | |
CN115029352A (en) | Method for breeding adgrg1 gene-deleted zebra fish through gene knockout | |
CN110438159B (en) | Construction method of gene mutation mouse model for inducing myofibrillar myopathy | |
CN111549070A (en) | Method for editing X chromosome multi-copy gene to realize animal sex control | |
CN108753833B (en) | Preparation method of zebra fish notch3 gene mutant | |
CN110643605B (en) | gRNA of megalobrama amblycephala MSTNa & b gene knockout and template thereof | |
CN114934073B (en) | Construction method and application of hoxa a gene knockout zebra fish mutant | |
CN111849977B (en) | Method for preparing transgenic animals by sperm vector, sgRNA for preparing short and small transgenic chickens and preparation method | |
CN113774128B (en) | Gja8 application of gene mutation site in preparation of product for diagnosing cataract disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |